Copenhagen, Denmark – Fresh data presented this week at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2026) suggest that patients with early Alzheimer’s disease continue to experience benefits from long-term treatment with lecanemab (U.S. Brand name: LEQEMBI®). The findings, shared by Eisai Co., Ltd., offer further insight into the potential of this anti-amyloid beta (Aβ) protofibril antibody as a treatment option for those in the early stages of the disease.
Eisai announced on March 10, 2026, that the latest research on lecanemab will be featured in six presentations at the conference, held in Copenhagen from March 17-21, and available online. These presentations include three oral presentations and will cover a range of topics related to the drug’s efficacy and safety.
Researchers will present findings from a U.S. Real-world study examining long-term treatment persistence with lecanemab, as well as outcomes for individuals carrying two copies of the apolipoprotein E ε4 (ApoEε4) gene – a genetic factor known to increase Alzheimer’s risk. The data could support clinicians better understand how to optimize treatment strategies for diverse patient populations.
four-year data from the Clarity AD Open-Label Extension trial, focusing on ApoEε4 non-carriers and heterozygotes, will be presented in poster format. A genome-wide association study identifying novel genetic variants linked to cognitive decline in Alzheimer’s disease will also be shared. These genetic insights could potentially lead to new therapeutic targets.
Eisai is also hosting an industry-sponsored symposium titled “Continue Life Their Way: Early Intervention in Alzheimer’s Disease,” featuring four leading global experts. The symposium will focus on the importance of early intervention, continuing treatment in the early stages of Alzheimer’s, and real-world outcomes.
These updates come as LEQEMBI continues to be a focus in Alzheimer’s treatment. LEQEMBI offers maintenance dosing options after 18 months of initial treatment, designed to continue slowing disease progression. The company highlights stories from patients and their families who are using the drug, emphasizing the importance of maintaining quality of life while living with early Alzheimer’s disease.
“I am doing my best to live my life to the fullest and adjust as necessary,” said Scott, a LEQEMBI patient, in a testimonial featured on the drug’s website. Other patients shared similar sentiments, expressing gratitude for the opportunity to continue engaging in activities they enjoy. These personal accounts underscore the potential impact of early intervention on individuals and their loved ones.
Further data on the long-term effects of LEQEMBI, presented at AD/PD™ 2026, will contribute to the growing body of evidence surrounding this treatment and its role in managing Alzheimer’s disease. The findings from Eisai’s research could inform clinical practice and improve outcomes for individuals affected by this devastating condition.
